Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease

Circulation

Volumn 94, Issue 3, 1996, Pages 316-322

  Wenzel, René R ^a   Duthiers, Nadine ^a   Noll, Georg ^a   Bucher, Julia ^a   Kaufmann, Urs ^a   Lüscher, Thomas F ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

coronary disease; diltiazem; endothelin; lasers; microcirculation

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; CALCIUM ANTAGONIST; DILTIAZEM; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG POTENCY; HUMAN; INTRADERMAL DRUG ADMINISTRATION; LASER DOPPLER FLOWMETRY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN; SKIN BLOOD FLOW; VASOCONSTRICTION; VASODILATATION;

EID: 0029789779     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.3.316     Document Type: Article

References (65)

1. Lüscher TF, Vanhoutte PM. The Endothelium: Modulator of Cardio-vascular Function. Boca Raton, Fla: CRC Press; 1990.
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332:411-415.
3. Yanagisawa M, Inoue A, Ishikawa T, Kasuya Y, Kimura S, Kumagaye S, Nakajima K, Watanabe TX, Sakakibara S, Goto K, Masaki T. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci USA. 1988;85:6964-6967.
4. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730-732.
5. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348:732-735.
6. Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, Fukami T, Ishikawa K, Nishikibe M, Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50:247-255.
7. Nakamichi K, Ihara M, Kobayashi M, Saeki T, Ishikawa K, Yano M. Different distribution of endothelin receptor subtypes in pulmonary tissues revealed by the novel selective ligands BQ-123 and [Ala1,3,11,15]ET-1. Biochem Biophys Res Commun. 1992;182:144-150.
8. Meyer P, Flammer J, Lüscher TF. Endothelium dependent regulation of the ophthalmic microcirculation in the perfused porcine eye: role of nitric oxide and endothelins. Invest Ophthalm Vis Sci. 1993; 34:3614-3621.
9. Clozel M, Gray GA, Breu V, Löffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun. 1992;186:867-873.
10. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89:1203-1208.
11. Vane J. Endothelins come home to roost. Nature. 1990;348:973-975. Comment.
12. Dohi Y, Lüscher TF. Endothelin in hypertensive resistance arteries: intraluminal and extraluminal dysfunction. Hypertension. 1991; 18:543-549.
13. De Nucci G, Thomas R, D'Orleans JP, Antunes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of ostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988;85:9797-9800.
14. Kiowski W, Lüscher TF, Linder L, Bühler FR. Endothelin-1-induced vasoconstriction in humans: reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation. 1991;83:469-475.
15. Nishikibe M, Tsuchida S, Okada M, Fukuroda T, Shimamoto K, Yano M, Ishikawa K, Ikemoto F. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 1993;52:717-724.
16. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhäusl W, Binder BR. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992;267:16066-16068.
17. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JJ. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.
18. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation. 1992;85:510-517.
19. Ziv I, Fleminger G, Djaldetti R, Achiron A, Melamed E, Sokolovsky M. Increased plasma endothelin-1 in acute ischemic stroke. Stroke. 1992;23:1014-1016.
20. Haak T, Jungmann E, Felber A, Hillmann U, Usadel KH. Increased plasma levels of endothelin in diabetic patients with hypertension. Am J Hypertens. 1992;5:161-166.
21. Stelzner TJ, O'Brien RF, Yanagisawa M, Sakurai T, Sato K, Webb S, Zamora M, McMurtry IF, Fisher JH. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol. 1992;262:614-620.
22. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
23. Goerre S, Wenk M, Bärtsch P, Lüscher TF, Niroomand S, Hohenhaus E, Oelz O, Reinhart WH. Endothelin-1 in pulmonary hypertension associated with high altitude. Circulation. 1994;90:359-364.
24. Cernacek P, Stewart DJ. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun. 1989;161:562-567.
25. Lechleitner P, Genser N, Mair J, Maier J, Artner DE, Dienstl F, Puschendorf B. Endothelin-1 in patients with complicated and uncomplicated myocardial infarction. Clin Invest. 1992;70:1070-1072.
26. Stewart DJ, Kubac G, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18:38-43.
27. Omland T, Terje Lie R, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89:1573-1579.
28. + exchange, c-fos expression, and mitogenesis in rat mesangial cells, J Clin Invest. 1989;83:708-712.
29. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989;78:225-228.
30. Takuwa N, Takuwa Y, Yanagisawa M, Yamashita K, Masaki T. A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts. J Biol Chem. 1989;264:7856-7861.
31. Muldoon LL, Pribnow D, Rodland KD, Magun BE. Endothelin-1 stimulates DNA synthesis and anchorage-independent growth of Rat-1 fibroblasts through a protein kinase C-dependent mechanism. Cell Regul. 1990;1:379-390.
32. Muldoon LL, Rodland KD, Forsythe ML, Magun BE. Stimulation of phosphatidylinositol hydrolysis, diacylglycerol release, and gene expression in response to endothelin, a potent new agonist for fibroblasts and smooth muscle cells. J Biol Chem. 1989;264:8529-8536.
33. Yang Z, Noll G, Lüscher TF. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation. 1993;8:832-836.
34. Godfraind T, Mennig D, Morel N, Wibo M. Effect of endothelin-1 on calcium channel gating by agonists in vascular smooth muscle. J Cardiovasc Pharmacol. 1989;13:S112-S117.
35. Yang Z, Bauer E, Von SL, Stulz P, Turina M, Lüscher TF. Different mobilization of calcium in endothelin-1-induced contractions in human arteries and veins: effects of calcium antagonists. J Cardiovasc Pharmacol. 1990;16:654-660.
36. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW, for the INTACT Group Investigators. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet. 1990;335:1109-1113.
37. Loaldi A, Polese A, Montorsi P, De Cesare N, Fabbiocchi F, Ravagnani P, Guazzi MD. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris. Am J Cardiol. 1989;64:433-439.
38. Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, Hudon G, Lemarbre L, Reitman M, Joyal M, Gosselin G, Dyrda I, Macer J, Havel RJ. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 1990;82:1940-1953.
39. Aramori I, Nirei H, Shoubo M, Sogabe K, Nakamura K, Kojo H, Notsu Y, Ono T, Nakanishi S. Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol. 1993;43: 127-131.
40. Cardell LO, Uddman R, Edvinsson L. A novel ETA-receptor antagonist, FR 139317, inhibits endothelin-induced contractions of guinea-pig pulmonary arteries, but not trachea. Br J Pharmacol. 1993;108:448-452.
41. Sogabe K, Nirei H, Shoubo M, Nomoto A, Ao S, Notsu Y, Ono T. Pharmacological profile of FR 139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1993;264: 1040-1046.
42. Eguchi S, Hirata Y, Ihara M, Yano M, Marumo F. A novel ETA antagonist (BQ-123) inhibits endothelin-1-induced phosphoinositide breakdown and DNA synthesis in rat vascular smooth muscle cells. FEBS Lett. 1992;302:243-246.
43. Hiley CR, Cowley DJ, Pelton JT, Hargreaves AC. BQ-123, cyclo-(D-Trp-D-Asp-Pro-D-Val-Leu), is a non-competitive antagonist of the actions of endothelin-1 in SK-N-MC human neuroblasloma cells. Biochem Biophys Res Commun. 1992;184:504-510.
44. Urade Y, Fujitani Y, Oda K, Watakabe T, Umemura I, Takai M, Okada T, Sakata K, Karaki H. An endothelin B receptor-selective antagonist: IRL 1038, [CysH-Cys15]-endothelin-1(11-21). FEBS Lett. 1992;311:12-16.
45. Warner TD, Allcock GH, Corder R, Vane JR. Use of the endothelin antagonists BQ-123 and PD142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol. 1993;110:777-782.
46. Clozel M, Breu V, Burri K, Cassal JM, Fischli W, Gray GA, Hirth G, Löffler BM, Muller M, Neidhart W, Ramuz H. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993;365:759-761.
47. B receptors. FEBS Lett. 1993;334:210-214.
48. B receptor antagonist (PD145065) and related analogues. Med Chem Res. 1993;3:154-162.
49. Doherty AM, Cody WL, DePue PL, He JX, Waite LA, Leonard DM, Leitz NL, Dudley DT, Rapundalo ST, Hingorani GP, Haleen SJ, LaDouceur DM, Hill KE, Flynn MA, Reynolds EE. Structure-activity relationships of C-terminal endothelin hexapeptide antagonists. J Med Chem. 1993;36:2585-2594.
50. Sun XY, Hedner T, Feng Q, Edvinsson L. Inhibition of endothelin (ET-1) induced presser responses by the endothelin (ETA) receptor antagonist FR 139317 in the pithed rat. Blood Press. 1992;1: 108-112.
51. Nilsson GE, Tenland T, Öberg PA. A new instrument for continuous measurement of tissue blood flow by light beating spectroscopy. IEEE Trans Biomed Eng. 1980;BME-27:12-19.
52. Nilsson GE, Tenland T, Öberg PA. Evaluation of a laser Doppler flowmeter for measurement of tissue blood flow. IEEE Trans Biomed Eng. 1980;BME-27:597-604.
53. Nilsson AL, Eriksson LE, Nilsson GE. Effects of local convective cooling and rewarming on skin blood flow. Int J Microcirc Clin Exp. 1986;5:11-25.
54. Stern MD. In vivo evaluation of microcirculation by coherent light scattering. Nature. 1975;254:56-58.
55. Wenzel RR, Noll G, Lüscher TF. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension. 1994;23:581-586.
56. Gordin A, Pohto P, Sundberg S, Nykanen S, Haataja H, Mannisto P. Pharmacokinetics of slow-release diltiazem and its effect on atrio-ventricular conduction in healthy volunteers. Eur J Clin Pharmacol. 1986;31:423-426.
57. Bighley LD, Dimmitt DC, McGraw BF. Bioavailability of diltiazem hydrochloride formulations. Clin Res. 1980;28:587A. Abstract2E
58. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation. 1995;91:941-947.
59. Zeiher AM, Ihling C, Pistorius K, Schachinger V, Schaefer HE. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet. 1994;344:1405-1406.
60. Crossman DC, Brain SD, Fuller RW. Potent vasoactive properties of endothelin 1 in human skin. J Appl Physiol. 1991;70:260-266.
61. Tschudi MR, Lüscher TF. Characterization of contractile endothelin and angiotensin receptors in human arteries: evidence for two dothelin and one angiotensin receptor. Biochem Biophys Res Commun. 1994;204:685-690.
62. Goto K, Kasuya Y, Matsuki N, Takuwa Y, Kurihara H, Ishikawa T, Kimura S, Yanagisawa M, Masaki T. Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca(2+) channel in vascular smooth muscle. Proc Natl Acad Sci U S A. 1989;86: 3915-3918.
63. Smith MS, Verghese CP, Shand DG, Pritchett ELC. Pharmacokinetic and pharmacodynamic effects of diltiazem. Am J Cardiol. 1983;51: 1369-1374.
64. Heagerty AM, Bund SJ, Aalkjaer C. Effects of drug treatment on human resistance arteriole morphology in essential hypertension: direct evidence for structural remodelling of resistance vessels. Lancet. 1988;2:1209-1212.
65. Ishikawa K, Fukami T, Nagase T, Fujita K, Hayama T, Niiyama K, Mase T, Ihara M, Yano M. Cyclic pentapeptide endothelin antagonists with high ETA selectivity, potency- and solubility-enhancing modifications. J Med Chem. 1992;35:2139-2142.